What is petrelintide?

An amylin drug, not another GLP-1

Nearly every obesity drug making headlines since 2023 has been a variation on the same theme: hit the GLP-1 receptor, then stack more receptors on top of it. Tirzepatide adds GIP. Retatrutide adds glucagon on top of that. Petrelintide skips the whole family. It is a selective agonist of the amylin receptor, developed under the internal code ZP8396 by Zealand Pharma, a Danish biotech, and now co-developed with Roche.

Amylin is a hormone your pancreas already makes, released alongside insulin every time you eat. It signals fullness through the area postrema, a region in the brainstem that reads circulating hormone levels directly rather than through the hypothalamic pathway GLP-1 relies on. That is a genuinely separate appetite circuit, which is the whole reason drug companies keep returning to amylin: a mechanism that does not overlap with GLP-1 is a mechanism that can be stacked on top of it later without redundancy.

What the Phase 2 ZUPREME-1 trial found

ZUPREME-1 enrolled 485 adults with obesity or overweight, randomized 5:1 to one of five petrelintide doses or placebo, dosed once weekly by subcutaneous injection. At week 42, the highest dose produced 10.7% mean weight loss against 1.7% for placebo. Every active dose separated from placebo, and Zealand reported the response curve was still climbing at the 42-week mark, not flattening out.

Zealand and Roche presented additional ZUPREME-1 detail at the American Diabetes Association's 2026 Scientific Sessions in June, reinforcing the tolerability signal alongside the weight-loss numbers. A second Phase 2 trial, ZUPREME-2, has topline data expected later in 2026 and should show whether the response holds in a different population.

Why the side-effect profile is the actual headline

10.7% weight loss on its own does not beat tirzepatide or semaglutide. What got Roche's attention was tolerability: researchers described the GI adverse event profile as "placebo-like," and only 1.5% of participants dropped out from GI side effects across the full 42 weeks. GLP-1 drugs routinely lose a meaningful share of patients to nausea and vomiting during dose escalation. If petrelintide can hold a double-digit weight-loss effect while avoiding that drop-off, it becomes valuable less as a standalone competitor and more as a foundation other drugs can be layered onto without adding GI burden.

Why Roche paid $1.65 billion upfront

In March 2025, Roche signed a global collaboration and license agreement with Zealand Pharma worth $1.65 billion upfront, with up to $5.3 billion more available across development milestones, regulatory milestones, and sales-based payments. The companies split profits 50/50 in the US and Europe, and Zealand collects tiered royalties elsewhere. Most of the near-term milestone money, roughly $1.2 billion of it, is tied to starting Phase 3 trials of petrelintide as a monotherapy, which is exactly what the April 2026 advancement announcement triggered.

That is a large bet for a drug that, alone, posts single-digit-to-low-double-digit weight loss. Roche is not betting on petrelintide replacing tirzepatide or semaglutide. It is betting on petrelintide becoming the tolerability layer underneath its own obesity portfolio.

The petrelintide-plus-enicepatide bet

Roche's own lead obesity drug is enicepatide (formerly CT-388), a GLP-1/GIP dual agonist that posted 22.5% weight loss data at ADA 2026 and is heading into Phase 3. The collaboration agreement with Zealand explicitly covers a fixed-dose combination of petrelintide and enicepatide, and a Phase 2 trial testing that combination is expected to begin around mid-2026.

The logic mirrors what Eli Lilly is doing by testing eloralintide as an add-on to tirzepatide: pair a strong metabolic driver (GLP-1/GIP) with an amylin drug that suppresses appetite through a separate brain circuit, in theory getting more weight loss without stacking GI side effects on top of GI side effects. Roche is running the same playbook with two drugs it now owns outright, rather than testing an amylin add-on against a rival's approved product.

How it differs from CagriSema and eloralintide

Novo Nordisk got to market first with the amylin idea through CagriSema, a fixed-dose combination of semaglutide and the amylin analog cagrilintide. Every CagriSema patient gets both mechanisms in one injection, whether they need both or not. Petrelintide, like eloralintide, is being developed as a standalone amylin drug first, which keeps the components separable: Roche can sell it alone, pair it with enicepatide, or eventually test it against a GLP-1 drug it does not own.

The distinction from eloralintide is mostly commercial rather than mechanistic. Both are selective amylin agonists dosed to skip GLP-1, GIP, and glucagon entirely. Lilly is building eloralintide around its own tirzepatide franchise. Roche is building petrelintide around enicepatide, a drug still working through Phase 3 itself. Whichever company gets a validated combination through trials first will have a real tolerability argument to make against the other's flagship product.

Where it stands now

Petrelintide is not going to out-perform tirzepatide or retatrutide on weight loss alone, and nobody involved is claiming otherwise. What it represents is Roche's answer to a problem every incretin drug shares: a meaningful share of patients cannot tolerate the GI side effects long enough to get results. A $1.65 billion upfront payment says Roche thinks solving that problem, even with a drug that tops out around 10.7% on its own, is worth more than chasing a bigger number through another GLP-1 variant. For where the rest of the obesity-drug field stands today, see retatrutide vs tirzepatide, or how peptide combinations are already being used off-label in peptide stacks.